Strategic Partnerships Precipio's recent collaboration with Memorial Sloan-Kettering Cancer Center underscores a focus on advancing diagnostic accuracy through innovative assays. This partnership presents opportunities to offer complementary technologies or diagnostic tools that can further enhance their clinical research and patient testing capabilities.

Expanding Diagnostic Portfolio The launch of the Quantitative BCR-ABL 2.0 panel and ongoing development of COVID-19 detection tests indicate Precipio's commitment to expanding its diagnostic offerings for cancer and infectious diseases. There is potential to promote additional or updated assays aligned with their product pipeline and clinical focus areas.

Enhancing Laboratory Services Precipio operates a CLIA/CAP certified laboratory that services hospitals and oncologists. Offering laboratory automation solutions, data management systems, or specialized testing equipment could attract their laboratory operations seeking efficiency improvements and advanced testing capabilities.

Regulatory and Data Security Following the recent data breach incident, there is a need for robust cybersecurity and compliance solutions. Providing secure data management solutions or consulting services can help Precipio strengthen its data protection measures and meet regulatory standards, opening a pathway for sales focused on data security.

Growth in Biotech Sector With revenue somewhere between 10 to 25 million dollars and a focused R&D approach, Precipio is poised for growth in the biotech diagnostics market. Opportunities exist to introduce advanced laboratory automation, software solutions, and reagent supply that support their R&D and clinical testing needs.